GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (WBO:GMAB) » Definitions » Cyclically Adjusted PB Ratio

Genmab A/S (WBO:GMAB) Cyclically Adjusted PB Ratio : 8.66 (As of Jun. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genmab A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-03), Genmab A/S's current share price is €258.70. Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €29.86. Genmab A/S's Cyclically Adjusted PB Ratio for today is 8.66.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:GMAB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 8.55   Med: 23.33   Max: 34.31
Current: 8.59

During the past years, Genmab A/S's highest Cyclically Adjusted PB Ratio was 34.31. The lowest was 8.55. And the median was 23.33.

WBO:GMAB's Cyclically Adjusted PB Ratio is ranked worse than
87.96% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs WBO:GMAB: 8.59

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab A/S's adjusted book value per share data for the three months ended in Mar. 2024 was €66.906. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €29.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted PB Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.77 29.31 22.44 17.77 10.22

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.57 13.80 12.53 10.22 9.25

Competitive Comparison of Genmab A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PB Ratio falls into.



Genmab A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=258.70/29.86
=8.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Genmab A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=66.906/118.4000*118.4000
=66.906

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.143 99.700 4.920
201409 4.572 99.700 5.430
201412 4.795 99.400 5.712
201503 5.966 100.200 7.050
201506 6.324 100.300 7.465
201509 6.870 100.200 8.118
201512 7.846 99.800 9.308
201603 7.910 100.200 9.347
201606 8.422 100.600 9.912
201609 8.778 100.200 10.372
201612 10.769 100.300 12.712
201703 11.099 101.200 12.985
201706 11.984 101.200 14.021
201709 12.027 101.800 13.988
201712 13.797 101.300 16.126
201803 14.316 101.700 16.667
201806 15.030 102.300 17.395
201809 15.476 102.400 17.894
201812 17.517 102.100 20.314
201903 17.706 102.900 20.373
201906 18.026 102.900 20.741
201909 25.795 102.900 29.681
201912 28.972 102.900 33.336
202003 29.613 103.300 33.942
202006 36.768 103.200 42.183
202009 38.022 103.500 43.496
202012 39.291 103.400 44.991
202103 41.317 104.300 46.903
202106 41.499 105.000 46.795
202109 43.777 105.800 48.991
202112 45.419 106.600 50.447
202203 46.475 109.900 50.070
202206 50.028 113.600 52.142
202209 54.409 116.400 55.344
202212 56.097 115.900 57.307
202303 56.006 117.300 56.531
202306 59.161 116.400 60.178
202309 63.873 117.400 64.417
202312 64.916 116.700 65.862
202403 66.906 118.400 66.906

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (WBO:GMAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (WBO:GMAB) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (WBO:GMAB) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Lester Murray Antman dba SimplyRich

By GuruFocus Research GuruFocus Editor 07-22-2022